Interaction Color Code
Clinical Bottom Line
Do not coadminister: Potential for reduced levels of elvitegravir / cobicistat
Drug 1
Drug 1 dose
200 mg daily x 2 weeks, 200 mg BID x 28 days
Drug 1 effect
Not studied
Drug 2 effect
Not studied
Clinical Effects
Potentially decreased or increased elvitegravir, cobicistat and / or nevirapine effects
Management
Use alternative agents
Import ID
607
